Free Trial
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

Dynavax Technologies logo
$12.72 -0.04 (-0.31%)
(As of 12/20/2024 05:16 PM ET)

About Dynavax Technologies Stock (NASDAQ:DVAX)

Key Stats

Today's Range
$12.68
$12.95
50-Day Range
$10.46
$13.66
52-Week Range
$9.74
$15.01
Volume
4.03 million shs
Average Volume
2.12 million shs
Market Capitalization
$1.67 billion
P/E Ratio
97.85
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Moderate Buy

Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
93rd Percentile Overall Score

DVAX MarketRank™: 

Dynavax Technologies scored higher than 93% of companies evaluated by MarketBeat, and ranked 72nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Dynavax Technologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about Dynavax Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Dynavax Technologies are expected to grow by 52.63% in the coming year, from $0.19 to $0.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dynavax Technologies is 97.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.74.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dynavax Technologies is 97.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 86.95.

  • Price to Book Value per Share Ratio

    Dynavax Technologies has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.62% of the outstanding shares of Dynavax Technologies have been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 14.76%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Dynavax Technologies does not currently pay a dividend.

  • Dividend Growth

    Dynavax Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.62% of the outstanding shares of Dynavax Technologies have been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 14.76%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Dynavax Technologies has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Dynavax Technologies this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Dynavax Technologies is held by insiders.

  • Percentage Held by Institutions

    96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dynavax Technologies' insider trading history.
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Dynavax announces $100M accelerated share repurchase program
Dynavax To Buyback $100 Mln Of Shares
See More Headlines

DVAX Stock Analysis - Frequently Asked Questions

Dynavax Technologies' stock was trading at $13.98 at the beginning of 2024. Since then, DVAX shares have decreased by 9.0% and is now trading at $12.72.
View the best growth stocks for 2024 here
.

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The biopharmaceutical company had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a net margin of 7.85% and a trailing twelve-month return on equity of 3.19%.

Top institutional shareholders of Dynavax Technologies include State Street Corp (5.85%), Chicago Capital LLC (4.19%), Geode Capital Management LLC (2.28%) and Mizuho Markets Americas LLC (1.05%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess.
View institutional ownership trends
.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/06/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
408
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$29.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+73.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-6,390,000.00
Pretax Margin
9.29%

Debt

Sales & Book Value

Annual Sales
$260.81 million
Book Value
$4.81 per share

Miscellaneous

Free Float
127,538,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
1.33

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:DVAX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners